GMS German Medical Science (Jan 2011)

Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis

  • Patrij, Katrin,
  • Kowoll, Annika,
  • Wätzel, Luise,
  • Reiser, Marcel,
  • Pels, Hendrik,
  • Linnebank, Michael,
  • Engert, Andreas,
  • Herrlinger, Ulrich,
  • Schackert, Gabriele,
  • Vogt-Schaden, Marlies,
  • Egerer, Gerlinde,
  • Lamprecht, Monika,
  • Batchelor, Tracy T.,
  • Schlegel, Uwe,
  • Schmidt-Wolf, Ingo G. H.,
  • International Primary CNS Lymphoma Collaborative Group (IPCG)

Journal volume & issue
Vol. 9
p. Doc11

Abstract

Read online

We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1–68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL).

Keywords